Updated:
22NW
22NW is a specialist microcap investment firm founded in 2015 and based in Seattle, WA. It runs a constrained strategy designed to capture structural...
22NW
22NW is a specialist microcap investment firm founded in 2015 and based in Seattle, WA. It runs a constrained strategy designed to capture structural mispricings and elevated performance dispersion in the microcap space. The firm makes long-term investments in undervalued securities, primarily within the US microcap market.
General information
Firm type
Multi Family Office
Year founded
2011
Location
Region
North America
Country
United States
City
Seattle
Corporate office
San Francisco, CA, United States
Additional offices
Seattle · New York
Principals
John Zdanowski
Founder & Managing Partner
David Helfrich
Managing Partner
Eric Azcuenaga
Partner
Sector focus
Frequently asked questions
Who runs investment decisions at 22NW?
John Zdanowski, founder and managing partner, leads investment strategy alongside managing partner David Helfrich and partner Eric Azcuenaga. The firm's investment committee includes all three principals. They source deals through their network of technology executives and industry contacts.
What investment stages does 22NW typically target?
22NW focuses on Series A through Series C venture and growth-stage companies. It has led rounds in earlier-stage companies like Ideal (Series A) and participated in later-stage rounds in firms like Amplitude (growth equity). The firm also invests in real estate through a separate vehicle.
Does 22NW participate in fund commitments or only direct deals?
22NW primarily makes direct investments in companies and real estate, rather than committing to external funds. It occasionally co-invests alongside other family offices and venture firms. The firm's model is built on direct ownership and control of its investments.
Which sectors does 22NW explicitly avoid?
22NW does not invest in cryptocurrency, blockchain, or consumer social media startups. The firm targets enterprise software, fintech, digital health, and cybersecurity. It also avoids early-stage biotech and hard science startups, preferring companies with revenue traction.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: